Nestle Answers FSSAI Over Lactogen Digestion Claim Probe
Nestle India recently submitted an exhaustive response to the regulator regarding its Lactogen digestion claim. The Food Safety and Standards Authority of India questioned packaging statements that whey protein is easy to digest. Consequently, the regulator demanded robust scientific evidence to substantiate these promotional claims.
Regulatory Scrutiny of the Lactogen Digestion Claim
The regulatory authority observed the digestion claims on both commercial packaging and digital promotional materials. Furthermore, officials directed the food business operator to submit supporting documentation within a stipulated timeframe. In recent months, the regulator intensified vigilance over infant food marketing across India. In addition, authorities issued similar show-cause notices to other leading nutrition manufacturers. Therefore, this action signals an assertive regulatory push to curb unverified nutritional declarations.
The IMS Act and Infant Nutrition Regulations
The regulator highlighted potential non-compliance with the Infant Milk Substitutes (IMS) Act of 1992, amended in 2003. Additionally, officials evaluated adherence to the Food Safety and Standards Regulations of 2020. Indian law strictly prohibits promotional claims designed to increase the commercial appeal of infant milk substitutes. Moreover, statutory provisions forbid marketing statements that attribute disease prevention or enhanced physiological benefits to breast milk substitutes. As a result, companies cannot assert unsubstantiated health benefits on infant formula packs.
Clinical Implications for Pediatric Practice
For pediatricians and healthcare providers, this regulatory development reinforces national infant feeding priorities. Breastfeeding remains the unrivaled gold standard for infant nutrition and gastrointestinal development. However, commercial formulas often advertise advanced digestive tolerance to anxious caregivers. Specifically, aggressive promotional statements can mislead parents into believing formula equals or surpasses maternal breast milk. Consequently, healthcare professionals must continue educating families about evidence-based infant feeding. Furthermore, clinicians should report unauthorized promotional practices that contravene the IMS Act.
Frequently Asked Questions
Q1: Why did FSSAI issue a notice regarding Lactogen Pro 1?
The regulator questioned the packaging claim stating that the product contains whey protein that is easy to digest, demanding scientific substantiation.
Q2: What Indian laws govern the promotion of infant milk substitutes?
The Infant Milk Substitutes (IMS) Act and the FSS (Foods for Infant Nutrition) Regulations govern and strictly restrict marketing claims for infant formula.
Q3: How has Nestle India responded to the regulatory notice?
Nestle India stated that it submitted a comprehensive response with scientific documentation to FSSAI within the stipulated timeframe.
References
- Nestle India submits response to FSSAI over Lactogen Pro 1 digestion claim - ETHealthworld
- Business Standard: FSSAI issues notices to Nestle India over Lactogen, Nan Excella claims
- The New Indian Express: FSSAI serves notices on Nestle India, others for misleading claims and promotion of infant milk substitutes
